Greenwich LifeSciences (Nasdaq: GLSI) reported a preliminary analysis from the open-label non-HLA-A*02 arm of FLAMINGO-01 showing an approximately 80% reduction in recurrence rate in the fully enrolled 250-patient arm by two analytic methods. Method 1 compared treated patients after the Primary Immunization Series to historical T-DM1 (KATHERINE) recurrence rates; Method 2 compared recurrence during the 6-month PIS (100 patient-years) to post-PIS follow-up (132 patient-years). The first patient completed all primary and booster vaccinations. Results are preliminary, the arm has no direct placebo comparator, and data are not completed or fully reviewed.